Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Citrine to Bring Treatment for Narcolepsy, a Rare Disease, to China

publication date: Oct 28, 2020

Citrine Medicine, a Shanghai rare disease startup, in-licensed China rights to a marketed treatment for narcolepsy and obstructive sleep apnea from Bioprojet SCR of Paris. In June, Citrine completed an $80 million Series A round led by Quan Capital to acquire products that address unmet needs for rare diseases. Citrine plans to develop a rare disease ecosystem that includes information, diagnosis and therapeutics. The company will have exclusive China rights to develop, market and manufacture Bioprojet's Wakix (pitolisant). Citrine was co-founded by Eight Roads, F-Prime Capital and Vivo Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital